



65 West Watkins Mill Road  
Gaithersburg, MD 20878  
tel: 240-632-0740  
fax: 240-632-0735  
www.genvec.com

**FOR IMMEDIATE RELEASE:**

**CONTACT:**

**Douglas J. Swirsky**  
**Chief Financial Officer**  
**(240) 632-5510**  
**dswirsky@genvec.com**

### **GENVEC RECEIVES GRANT FOR PEDF PROGRAM**

**GAITHERSBURG, MD** – May 21, 2008 – GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a grant from the National Eye Institute (NEI), of the National Institutes of Health (NIH), to explore mechanisms regulating pigment epithelium-derived factor (PEDF), a key regulator of blood vessel growth in the eye. This grant valued at approximately \$546,000 over two years, will support research being conducted at GenVec.

Dr. Rick King, GenVec's Senior Vice President of Research, stated, "A key objective of this grant is to expand our understanding of how PEDF influences blood vessel growth in the eye." Uncontrolled growth of new blood vessels is a factor in diabetic retinopathy and macular degeneration, the leading causes of blindness in the Western world. King added, "We believe that research conducted under this grant may lead to the discovery and testing of improved strategies to treat neovascular diseases of the eye."

#### ***About GenVec***

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product candidate, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer and is being evaluated in additional clinical trials in other tumor types. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus

(RSV), and influenza. Additional information about GenVec is available at [www.genvec.com](http://www.genvec.com) and in the company's various filings with the Securities and Exchange Commission.

*Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at [www.sec.gov](http://www.sec.gov). These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.*

###